Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial

MLA

Amel Karaa, et al. “Genotype-Specific Effects of Elamipretide in Patients with Primary Mitochondrial Myopathy: A Post Hoc Analysis of the MMPOWER-3 Trial.” Orphanet Journal of Rare Diseases, vol. 19, no. 1, Nov. 2024, pp. 1–12. EBSCOhost, https://doi.org/10.1186/s13023-024-03421-5.

APA

Amel Karaa, Enrico Bertini, Valerio Carelli, Bruce Cohen, Gregory M. Ennes, Marni J. Falk, Amy Goldstein, Gráinne Gorman, Richard Haas, Michio Hirano, Thomas Klopstock, Mary Kay Koenig, Cornelia Kornblum, Costanza Lamperti, Anna Lehman, Nicola Longo, Maria Judit Molnar, Sumit Parikh, Han Phan, … on behalf of the MMPOWER-3 Trial Investigators. (2024). Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial. Orphanet Journal of Rare Diseases, 19(1), 1–12. https://doi.org/10.1186/s13023-024-03421-5

Chicago

Amel Karaa, Enrico Bertini, Valerio Carelli, Bruce Cohen, Gregory M. Ennes, Marni J. Falk, Amy Goldstein, et al. 2024. “Genotype-Specific Effects of Elamipretide in Patients with Primary Mitochondrial Myopathy: A Post Hoc Analysis of the MMPOWER-3 Trial.” Orphanet Journal of Rare Diseases 19 (1): 1–12. doi:10.1186/s13023-024-03421-5.